Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling
- PMID: 29170395
- PMCID: PMC5701070
- DOI: 10.1038/s41467-017-02002-4
Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling
Abstract
Mutations in PIK3CA are very frequent in cancer and lead to sustained PI3K pathway activation. The impact of acute expression of mutant PIK3CA during early stages of malignancy is unknown. Using a mouse model to activate the Pik3ca H1047R hotspot mutation in the heterozygous state from its endogenous locus, we here report that mutant Pik3ca induces centrosome amplification in cultured cells (through a pathway involving AKT, ROCK and CDK2/Cyclin E-nucleophosmin) and in mouse tissues, and increased in vitro cellular tolerance to spontaneous genome doubling. We also present evidence that the majority of PIK3CA H1047R mutations in the TCGA breast cancer cohort precede genome doubling. These previously unappreciated roles of PIK3CA mutation show that PI3K signalling can contribute to the generation of irreversible genomic changes in cancer. While this can limit the impact of PI3K-targeted therapies, these findings also open the opportunity for therapeutic approaches aimed at limiting tumour heterogeneity and evolution.
Conflict of interest statement
B.V. is a consultant to Karus Therapeutics (Oxford, UK). C.S. discloses consulting and/or speaker fees from: Novartis, Eli Lilly, Roche, Pfizer, Celgene, Boehringer Ingelheim and Servier, and Scientific Advisory Board/ Stock options from: APOGEN Biotechnologies, EPIC Biosciences GRAIL, Achilles Therapeutics (co-founder and stock options). The remaining authors declare no competing financial interests.
Figures









References
-
- Okkenhaug K, Graupera M, Vanhaesebroeck B. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discov. 2016;6:1090–1105. doi: 10.1158/2159-8290.CD-16-0716. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 24956/CRUK_/Cancer Research UK/United Kingdom
- 097721/Z/11/Z/WT_/Wellcome Trust/United Kingdom
- MR/P014712/1/MRC_/Medical Research Council/United Kingdom
- MRC_MC_UU_12012/5/MRC_/Medical Research Council/United Kingdom
- WT_/Wellcome Trust/United Kingdom
- 19310/CRUK_/Cancer Research UK/United Kingdom
- WT098498/WT_/Wellcome Trust/United Kingdom
- BB/J00989X/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- C1295/ A15937/CRUK_/Cancer Research UK/United Kingdom
- 20466/CRUK_/Cancer Research UK/United Kingdom
- BB/F011512/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- 103788/Z/14/Z/WT_/Wellcome Trust/United Kingdom
- 17786/CRUK_/Cancer Research UK/United Kingdom
- C23338/A15965/CRUK_/Cancer Research UK/United Kingdom
- 15965/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous